[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-001", "question": "A 45-year-old woman presents with progressive bilateral hearing loss, facial numbness, and ataxia. MRI reveals bilateral enhancing cerebellopontine angle masses with significant brainstem compression. Genetic testing confirms a missense mutation in the SMARCB1 gene. After maximal safe resection of the larger tumor, which management strategy offers the best long-term tumor control while preserving neurological function?", "options": ["Treatment with a selective histone deacetylase 6 (HDAC6) inhibitor", "Initiation of mTOR complex 1/2 dual inhibitor therapy", "Conformal radiotherapy targeting both lesions with dose painting", "Observation with serial MRI and consideration of bevacizumab for symptom control", "Prophylactic ventriculoperitoneal shunting followed by chemotherapy with carboplatin/vincristine"], "answer": "A", "answer_index": 0, "explanation": "The clinical scenario describes schwannomatosis due to SMARCB1 mutation. HDAC6 inhibitors have shown specific efficacy in preclinical models of SMARCB1-deficient tumors by restoring protein homeostasis and inducing apoptosis, unlike broader epigenetic modifiers. mTOR inhibitors are more relevant for NF2-related schwannomas, while radiotherapy is contraindicated in schwannomatosis due to malignant transformation risk. Bevacizumab has limited efficacy in SMARCB1-mutant tumors compared to NF2-mutant schwannomas.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer\\nKey stem clues: 45-year-old woman; progressive bilateral hearing loss, facial numbness, ataxia; bilateral enhancing cerebellopontine angle masses with brainstem compression; SMARCB1 missense mutation; post–maximal safe resection; ask for best long-term tumor control while preserving neurologic function.\\nThe vignette suggests multiple vestibular schwannomas with an SMARCB1 mutation (schwannomatosis variant). However, none of the listed management options reflects an established, evidence-based standard of care. A selective HDAC6 inhibitor (A) is experimental, not routine or proven “best long-term tumor control.” mTORC1/2 dual inhibitors (B) are also investigational. Conformal radiotherapy (C) is sometimes used for vestibular schwannomas, but the explanation asserts it is contraindicated in schwannomatosis due to malignant transformation risk—this is controversial and not firmly guideline-based, and the stem does not state such a constraint. Observation plus bevacizumab (D) is also extrapolated and not clearly best for SMARCB1 disease. Prophylactic VP shunt with carboplatin/vincristine (E) is inappropriate.\\nMain issue: the question asks for a current best management but all options are either incorrect, investigational, or poorly supported; thus no option is convincingly defensible.\\nMinimal fix: Replace option C (or add a new option) with a guideline-concordant approach such as stereotactic radiosurgery of residual/progressive lesions and key that answer.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer\nKey stem clues: 45-year-old woman; progressive bilateral hearing loss, facial numbness, ataxia; bilateral enhancing cerebellopontine angle masses with brainstem compression; SMARCB1 missense mutation; post–maximal safe resection; ask for best long-term tumor control while preserving neurologic function.\nThe vignette suggests multiple vestibular schwannomas with an SMARCB1 mutation (schwannomatosis variant). However, none of the listed management options reflects an established, evidence-based standard of care. A selective HDAC6 inhibitor (A) is experimental, not routine or proven “best long-term tumor control.” mTORC1/2 dual inhibitors (B) are also investigational. Conformal radiotherapy (C) is sometimes used for vestibular schwannomas, but the explanation asserts it is contraindicated in schwannomatosis due to malignant transformation risk—this is controversial and not firmly guideline-based, and the stem does not state such a constraint. Observation plus bevacizumab (D) is also extrapolated and not clearly best for SMARCB1 disease. Prophylactic VP shunt with carboplatin/vincristine (E) is inappropriate.\nMain issue: the question asks for a current best management but all options are either incorrect, investigational, or poorly supported; thus no option is convincingly defensible.\nMinimal fix: Replace option C (or add a new option) with a guideline-concordant approach such as stereotactic radiosurgery of residual/progressive lesions and key that answer.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-002", "question": "A 68-year-old man with locally advanced pancreatic cancer involving the celiac axis undergoes stereotactic body radiotherapy (SBRT) to 40 Gy in 5 fractions. Three months later, he develops severe epigastric pain and hematemesis. Endoscopy reveals a deeply ulcerated lesion in the gastric antrum with visible vessel. Biopsy shows radiation-induced changes without malignancy. Which interventional approach is most likely to achieve durable hemostasis while minimizing the risk of gastric perforation?", "options": ["Over-the-scope clip placement with concomitant fibrin glue injection", "Hybrid argon plasma coagulation combined with topical hemostatic powder", "Selective angiography with coil embolization of the gastroduodenal artery", "Endoscopic ultrasound-guided cyanoacrylate injection into the peri-ulcer bed", "Temporary covered esophageal stent placement with nasojejunal feeding tube"], "answer": "D", "answer_index": 3, "explanation": "After high-dose SBRT, conventional endoscopic therapies often fail due to compromised tissue healing. EUS-guided cyanoacrylate injection directly targets the feeding vessel deep within the ulcer bed, creating a permanent seal without the tissue disruption caused by thermal modalities. Over-the-scope clips may not hold in friable irradiated tissue, while angiographic embolization risks non-target ischemia. Topical agents provide only temporary control in this high-flow scenario.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 68-year-old with locally advanced pancreatic cancer treated with high-dose SBRT to 40 Gy/5 fx; delayed severe epigastric pain and hematemesis; endoscopy shows deeply ulcerated gastric antral lesion with visible vessel; biopsy reveals radiation-induced changes (no tumor). Question asks for an interventional approach that gives durable hemostasis while minimizing gastric perforation risk, considering irradiated, friable tissue and a high‑risk visible vessel.\\nEUS-guided cyanoacrylate injection (D) is defensible as best: it allows targeted obliteration of the feeding vessel with minimal additional mucosal trauma, appropriate for radiation-induced, deep ulcer bleeding where clips/thermal modalities may fail or risk perforation.\\nOption A (OTSC + fibrin) relies on mechanical closure in friable irradiated tissue and may not seat securely. B (argon plasma + powder) are superficial, less suitable for high-flow, deep-vessel bleeding and increase thermal damage. C (gastroduodenal artery embolization) risks extensive gastric/duodenal ischemia in already-compromised vasculature. E (esophageal stent) does not address a gastric antral source.\\nNo logical contradictions or equally strong alternatives; the keyed answer matches the unique best choice.\\nMinimal fix: Add a brief note that prior standard endoscopic hemostasis attempts were unstable or high-risk to further justify the need for a vessel-directed, non-thermal modality like EUS-guided cyanoacrylate injection.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 68-year-old with locally advanced pancreatic cancer treated with high-dose SBRT to 40 Gy/5 fx; delayed severe epigastric pain and hematemesis; endoscopy shows deeply ulcerated gastric antral lesion with visible vessel; biopsy reveals radiation-induced changes (no tumor). Question asks for an interventional approach that gives durable hemostasis while minimizing gastric perforation risk, considering irradiated, friable tissue and a high‑risk visible vessel.\nEUS-guided cyanoacrylate injection (D) is defensible as best: it allows targeted obliteration of the feeding vessel with minimal additional mucosal trauma, appropriate for radiation-induced, deep ulcer bleeding where clips/thermal modalities may fail or risk perforation.\nOption A (OTSC + fibrin) relies on mechanical closure in friable irradiated tissue and may not seat securely. B (argon plasma + powder) are superficial, less suitable for high-flow, deep-vessel bleeding and increase thermal damage. C (gastroduodenal artery embolization) risks extensive gastric/duodenal ischemia in already-compromised vasculature. E (esophageal stent) does not address a gastric antral source.\nNo logical contradictions or equally strong alternatives; the keyed answer matches the unique best choice.\nMinimal fix: Add a brief note that prior standard endoscopic hemostasis attempts were unstable or high-risk to further justify the need for a vessel-directed, non-thermal modality like EUS-guided cyanoacrylate injection.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-003", "question": "A 52-year-old man undergoes right pneumonectomy for T3N2M0 non-small cell lung cancer. On postoperative day 4, he develops acute respiratory distress. Chest tube output abruptly decreases, and the mediastinum shifts toward the left on radiograph. Bronchoscopy reveals a 1.5 cm dehiscence of the bronchial stump without frank disruption. What is the most appropriate immediate management?", "options": ["Emergency rethoracotomy with direct stump revision", "Placement of a second chest tube to water seal", "Immediate bedside reopening of the incision with antibiotic irrigation", "Flexible bronchoscopic placement of an endobronchial valve in the right main bronchus", "Urgent veno-venous ECMO cannulation followed by operative repair"], "answer": "C", "answer_index": 2, "explanation": "This scenario describes a post-pneumonectomy bronchopleural fistula with impending tension physiology. Immediate bedside reopening allows mediastinal decompression and converts the situation to an open pleural cavity, preventing fatal tension. This is followed by formal operative repair after stabilization. Endobronchial valves are ineffective for large proximal dehiscences. Re-thoracotomy without decompression risks cardiovascular collapse. ECMO is reserved for refractory respiratory failure after initial stabilization.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: recent right pneumonectomy (only one lung remaining), POD 4, acute respiratory distress, abrupt fall in chest tube output, mediastinal shift toward the left (toward the intact lung → tension hydropneumothorax / post-pneumonectomy space under pressure), and 1.5-cm bronchial stump dehiscence. This describes a post-pneumonectomy bronchopleural fistula with evolving tension physiology, where the immediate life‑threatening issue is mediastinal compression rather than definitive stump repair.\\n\\nChoice C (bedside reopening of the incision with irrigation) is the best immediate management because it rapidly decompresses the post‑pneumonectomy space and converts it to an open cavity, relieving tension and stabilizing the patient before formal re-exploration and repair. A (emergency rethoracotomy) delays decompression in an unstable patient and risks cardiovascular collapse during induction/positioning. B (second chest tube) is typically ineffective with a large stump dehiscence and cannot guarantee rapid decompression. D (endobronchial valve) does not address large proximal defects and tension. E (VV-ECMO) is excessive and not first-line for tension physiology.\\n\\nMain medical accuracy issues: None significant; management sequence and contraindications are in line with thoracic surgery teaching.\\n\\nMinimal fix: Explicitly state he is hemodynamically unstable (e.g., hypotensive) to further justify emergency bedside decompression as the priority step.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: recent right pneumonectomy (only one lung remaining), POD 4, acute respiratory distress, abrupt fall in chest tube output, mediastinal shift toward the left (toward the intact lung → tension hydropneumothorax / post-pneumonectomy space under pressure), and 1.5-cm bronchial stump dehiscence. This describes a post-pneumonectomy bronchopleural fistula with evolving tension physiology, where the immediate life‑threatening issue is mediastinal compression rather than definitive stump repair.\n\nChoice C (bedside reopening of the incision with irrigation) is the best immediate management because it rapidly decompresses the post‑pneumonectomy space and converts it to an open cavity, relieving tension and stabilizing the patient before formal re-exploration and repair. A (emergency rethoracotomy) delays decompression in an unstable patient and risks cardiovascular collapse during induction/positioning. B (second chest tube) is typically ineffective with a large stump dehiscence and cannot guarantee rapid decompression. D (endobronchial valve) does not address large proximal defects and tension. E (VV-ECMO) is excessive and not first-line for tension physiology.\n\nMain medical accuracy issues: None significant; management sequence and contraindications are in line with thoracic surgery teaching.\n\nMinimal fix: Explicitly state he is hemodynamically unstable (e.g., hypotensive) to further justify emergency bedside decompression as the priority step.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-004", "question": "A 74-year-old man with a history of abdominal aortic aneurysm repair presents with acute onset of painful blue discoloration of his toes despite palpable pedal pulses. Laboratory studies show elevated creatinine kinase and acute kidney injury. Angiography demonstrates patent bypass graft but diffuse microvascular occlusion in both feet. What is the most appropriate emergent intervention?", "options": ["Immediate bilateral sympathectomy", "Systemic heparinization followed by catheter-directed thrombolysis", "High-dose corticosteroid pulse therapy", "Emergent surgical embolectomy of the tibial vessels", "Plasma exchange with albumin replacement"], "answer": "E", "answer_index": 4, "explanation": "The presentation is consistent with cholesterol embolization syndrome following aortic manipulation. Plasma exchange removes inflammatory mediators and cholesterol-laden microemboli, improving microcirculatory flow. Thrombolysis is ineffective for cholesterol crystals and increases hemorrhage risk. Sympathectomy helps vasospasm but doesn't address the embolic load. Corticosteroids may modestly reduce inflammation but don't remove emboli. Surgical embolectomy cannot access distal microvasculature.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Not defensible as best; item likely mis-teaches management of cholesterol embolization.\\nKey stem clues: Elderly man, prior AAA repair, acute painful blue toes with palpable pulses (“blue toe syndrome”), angiography with patent graft and diffuse microvascular occlusion, acute kidney injury and elevated CK – classic for cholesterol crystal embolization / atheroembolism rather than thrombotic occlusion.\\nMain logical/medical issues: Standard management of cholesterol embolization is largely supportive: risk-factor control, stop anticoagulation/thrombolytics, pain management, and treat organ dysfunction. Plasma exchange is not established emergent standard of care; evidence is limited and not guideline-based. None of the listed options represents a widely accepted emergent intervention. Systemic heparin with thrombolysis and surgical embolectomy are inappropriate for cholesterol crystals; sympathectomy and steroids are nonstandard/adjunctive at best. Thus, there is effectively no clearly correct answer among given choices.\\nMinimal fix: Replace option E with “Supportive care with discontinuation of anticoagulation and management of end-organ damage” and key that; alternatively, reframe stem to a context where plasmapheresis is specifically indicated by evidence or guidelines, or change key to a truly evidence-based therapy if available in options.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Not defensible as best; item likely mis-teaches management of cholesterol embolization.\nKey stem clues: Elderly man, prior AAA repair, acute painful blue toes with palpable pulses (“blue toe syndrome”), angiography with patent graft and diffuse microvascular occlusion, acute kidney injury and elevated CK – classic for cholesterol crystal embolization / atheroembolism rather than thrombotic occlusion.\nMain logical/medical issues: Standard management of cholesterol embolization is largely supportive: risk-factor control, stop anticoagulation/thrombolytics, pain management, and treat organ dysfunction. Plasma exchange is not established emergent standard of care; evidence is limited and not guideline-based. None of the listed options represents a widely accepted emergent intervention. Systemic heparin with thrombolysis and surgical embolectomy are inappropriate for cholesterol crystals; sympathectomy and steroids are nonstandard/adjunctive at best. Thus, there is effectively no clearly correct answer among given choices.\nMinimal fix: Replace option E with “Supportive care with discontinuation of anticoagulation and management of end-organ damage” and key that; alternatively, reframe stem to a context where plasmapheresis is specifically indicated by evidence or guidelines, or change key to a truly evidence-based therapy if available in options.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-005", "question": "A 38-year-old woman with Crohn's disease maintained on vedolizumab presents with recurrent episodes of postprandial abdominal pain and 15-pound weight loss. CT enterography shows patent superior mesenteric artery and vein. Gastric emptying study is normal. Diagnostic laparoscopy reveals no adhesions. Which test will most likely establish the diagnosis?", "options": ["Mesenteric Doppler ultrasound with a standardized meal challenge", "Lactulose hydrogen breath test for small intestinal bacterial overgrowth", "Serum tryptase level during symptomatic episode", "Selective mesenteric angiography with vasodilator challenge", "Video capsule endoscopy with patency capsule confirmation"], "answer": "A", "answer_index": 0, "explanation": "This presentation suggests chronic mesenteric ischemia despite patent gross vasculature, possibly from vedolizumab-associated microvascular dysfunction. Provocative mesenteric Doppler can demonstrate reduced postprandial flow reserve. While bacterial overgrowth is common in Crohn's, it doesn't explain the postprandial timing. Angiography shows macrovascular disease already ruled out. Capsule endoscopy may show mucosal changes but doesn't assess flow dynamics. Tryptase would indicate mast cell disorder, which is less likely.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Crohn’s disease on vedolizumab; recurrent postprandial abdominal pain; significant weight loss; CT enterography with patent SMA/SMV (macrovascular disease excluded); normal gastric emptying; no adhesions on laparoscopy. The question asks which test will most likely establish the diagnosis in a patient whose symptoms suggest chronic mesenteric ischemia despite normal large-vessel imaging.\\nMesenteric Doppler ultrasound with standardized meal challenge (A) is the only option that specifically evaluates dynamic, postprandial mesenteric flow reserve and can detect functional/microvascular ischemia when major vessels appear patent, matching the described pathophysiology and timing.\\nB (SIBO breath test) could cause nonspecific bloating/diarrhea and is not characteristically postprandial ischemic pain; plus vascular workup focus argues against it as best. C (serum tryptase) targets mast cell disorders without strong support from stem. D (selective mesenteric angiography) is aimed at macrovascular occlusive disease already excluded by CT; vasodilator challenge for microvascular dysfunction is not standard. E (capsule endoscopy) visualizes mucosa but does not assess flow dynamics and has lower yield for this functional suspicion.\\nMain medical issue: vedolizumab-associated microvascular dysfunction is somewhat speculative but not clearly incorrect. Minimal fix: briefly mention suspicion of microvascular/functional mesenteric ischemia in the stem to better justify the provocative flow study focus.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Crohn’s disease on vedolizumab; recurrent postprandial abdominal pain; significant weight loss; CT enterography with patent SMA/SMV (macrovascular disease excluded); normal gastric emptying; no adhesions on laparoscopy. The question asks which test will most likely establish the diagnosis in a patient whose symptoms suggest chronic mesenteric ischemia despite normal large-vessel imaging.\nMesenteric Doppler ultrasound with standardized meal challenge (A) is the only option that specifically evaluates dynamic, postprandial mesenteric flow reserve and can detect functional/microvascular ischemia when major vessels appear patent, matching the described pathophysiology and timing.\nB (SIBO breath test) could cause nonspecific bloating/diarrhea and is not characteristically postprandial ischemic pain; plus vascular workup focus argues against it as best. C (serum tryptase) targets mast cell disorders without strong support from stem. D (selective mesenteric angiography) is aimed at macrovascular occlusive disease already excluded by CT; vasodilator challenge for microvascular dysfunction is not standard. E (capsule endoscopy) visualizes mucosa but does not assess flow dynamics and has lower yield for this functional suspicion.\nMain medical issue: vedolizumab-associated microvascular dysfunction is somewhat speculative but not clearly incorrect. Minimal fix: briefly mention suspicion of microvascular/functional mesenteric ischemia in the stem to better justify the provocative flow study focus.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-006", "question": "A 65-year-old man presents with acute severe hematochezia. Colonoscopy reveals active bleeding from a non-ulcerated lesion in the ascending colon with a visible vessel. Biopsy shows dilated submucosal veins without evidence of vasculitis or neoplasia. CT angiography shows no arterial malformation. What is the most appropriate endoscopic therapy?", "options": ["Heater probe coagulation with high power settings", "Endoscopic band ligation of the lesion", "Injection of N-butyl-2-cyanoacrylate glue", "Placement of through-the-scope clips in a circumferential pattern", "Argon plasma coagulation with extended application time"], "answer": "B", "answer_index": 1, "explanation": "The findings are characteristic of Dieulafoy's lesion of the colon, which involves a abnormally large submucosal artery. Endoscopic band ligation is superior to thermal or clipping methods as it mechanically secures the vessel with low recurrence rates. Cyanoacrylate injection risks embolization in this location. Thermal methods may not adequately coagulate the large caliber vessel. Clips may not achieve full-thickness compression needed for this lesion type.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed), secondary U. Verdict on keyed answer: Miskeyed; another option is more defensible. Key stem clues: 65-year-old with acute severe hematochezia; non-ulcerated ascending colon lesion with visible vessel; biopsy shows dilated submucosal veins; CT angio shows no arterial malformation. These findings are more consistent with a colonic angiodysplasia (dilated submucosal veins) rather than a Dieulafoy lesion (large caliber artery protruding through a mucosal defect). Standard endoscopic treatment for colonic angiodysplasia is argon plasma coagulation, making option E the best-supported choice. The keyed rationale incorrectly identifies the lesion as Dieulafoy and describes it as an abnormally large submucosal artery, contradicting the venous histology given. Band ligation is not the established first-line therapy for colonic angiodysplasia. Main medical accuracy issue: incorrect pathologic characterization and mismatched therapy. Minimal fix: Change the biopsy description to “a large-caliber submucosal artery protruding through a minute mucosal defect without surrounding inflammation or neoplasia” to match Dieulafoy lesion, or alternatively change the key to E and explanation to angiodysplasia treated with argon plasma coagulation.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed), secondary U. Verdict on keyed answer: Miskeyed; another option is more defensible. Key stem clues: 65-year-old with acute severe hematochezia; non-ulcerated ascending colon lesion with visible vessel; biopsy shows dilated submucosal veins; CT angio shows no arterial malformation. These findings are more consistent with a colonic angiodysplasia (dilated submucosal veins) rather than a Dieulafoy lesion (large caliber artery protruding through a mucosal defect). Standard endoscopic treatment for colonic angiodysplasia is argon plasma coagulation, making option E the best-supported choice. The keyed rationale incorrectly identifies the lesion as Dieulafoy and describes it as an abnormally large submucosal artery, contradicting the venous histology given. Band ligation is not the established first-line therapy for colonic angiodysplasia. Main medical accuracy issue: incorrect pathologic characterization and mismatched therapy. Minimal fix: Change the biopsy description to “a large-caliber submucosal artery protruding through a minute mucosal defect without surrounding inflammation or neoplasia” to match Dieulafoy lesion, or alternatively change the key to E and explanation to angiodysplasia treated with argon plasma coagulation.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-007", "question": "A 55-year-old man with autosomal dominant polycystic kidney disease (ADPKD) and estimated glomerular filtration rate of 35 mL/min/1.73m² presents with acute left flank pain. CT shows a 8cm left renal cyst with hyperdense material and a fluid-debris level. Urinalysis shows 25-50 white blood cells but no bacteria. He is afebrile with normal blood pressure. What is the most appropriate management?", "options": ["Immediate initiation of ciprofloxacin", "Percutaneous drainage with cyst fluid culture", "CT-guided aspiration for cytology", "Hospital admission for intravenous ampicillin-sulbactam", "Analgesia and follow-up imaging in 4-6 weeks"], "answer": "B", "answer_index": 1, "explanation": "This presentation suggests an infected renal cyst in ADPKD, which requires drainage for both diagnosis and therapy. Cyst infections often present with minimal systemic signs in ADPKD patients. Antibiotics alone penetrate cysts poorly. Percutaneous drainage confirms the diagnosis, provides targeted therapy, and prevents sepsis. Aspiration for cytology would miss infection. Observation risks abscess formation. IV antibiotics without drainage are unlikely to eradicate the infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: ADPKD, eGFR 35 (CKD 3b), acute flank pain, 8‑cm cyst with hyperdense material and fluid–debris level, pyuria without bacteriuria, afebrile and hemodynamically stable. CT description and pyuria suggest hemorrhagic or possibly infected cyst; absence of fever, leukocytosis, or sepsis markers argues against clear acute infection requiring immediate invasive therapy.\\nLogical issues: The explanation asserts a cyst infection despite no systemic signs and only mild urinary findings, yet infected cysts in ADPKD typically present with fever and systemic inflammation. The imaging can also be compatible with a hemorrhagic cyst, for which conservative management with analgesia and follow-up imaging (choice E) is standard. Without labs (WBC, CRP), cultures, or fever, the stem is underspecified to distinguish infection vs hemorrhage. Thus both B (if infected cyst) and E (if hemorrhagic cyst) are defensible, and no single best answer is forced by the vignette.\\nMedical accuracy: The statements about poor antibiotic penetration into cysts and role of drainage in proven infected cysts are accurate, but the diagnostic inference from this stem is weak.\\nMinimal fix: Add fever and elevated CRP/WBC, or blood culture positivity, to clearly indicate infected cyst and justify drainage (B).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: ADPKD, eGFR 35 (CKD 3b), acute flank pain, 8‑cm cyst with hyperdense material and fluid–debris level, pyuria without bacteriuria, afebrile and hemodynamically stable. CT description and pyuria suggest hemorrhagic or possibly infected cyst; absence of fever, leukocytosis, or sepsis markers argues against clear acute infection requiring immediate invasive therapy.\nLogical issues: The explanation asserts a cyst infection despite no systemic signs and only mild urinary findings, yet infected cysts in ADPKD typically present with fever and systemic inflammation. The imaging can also be compatible with a hemorrhagic cyst, for which conservative management with analgesia and follow-up imaging (choice E) is standard. Without labs (WBC, CRP), cultures, or fever, the stem is underspecified to distinguish infection vs hemorrhage. Thus both B (if infected cyst) and E (if hemorrhagic cyst) are defensible, and no single best answer is forced by the vignette.\nMedical accuracy: The statements about poor antibiotic penetration into cysts and role of drainage in proven infected cysts are accurate, but the diagnostic inference from this stem is weak.\nMinimal fix: Add fever and elevated CRP/WBC, or blood culture positivity, to clearly indicate infected cyst and justify drainage (B).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-008", "question": "A 28-year-old woman develops recurrent sinopulmonary infections and bronchiectasis. Workup reveals absent IgA, markedly reduced IgG and IgM, and absent B cells on flow cytometry. Genetic testing identifies a mutation in the λ5 surrogate light chain gene. Which specific immunological abnormality explains her infection pattern?", "options": ["Failure of heavy chain rearrangement in pre-B cells", "Defective VDJ recombination due to RAG deficiency", "Absence of the pre-B cell receptor complex signaling", "Mutation in the BLNK adapter protein preventing PLCγ activation", "Loss of BTK enzyme function disrupting B cell maturation"], "answer": "C", "answer_index": 2, "explanation": "The λ5 gene encodes part of the surrogate light chain critical for pre-B cell receptor formation. Without functional pre-BCR signaling, B cells fail to proliferate and mature at the pre-B cell stage, causing the arrested development seen here. This is distinct from Bruton's tyrosine kinase deficiency (which affects later signaling) or RAG deficiencies (which impair initial recombination). The specific λ5 mutation explains the profound B cell deficiency and hypogammaglobulinemia.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 28-year-old woman with recurrent sinopulmonary infections and bronchiectasis; labs show absent IgA, markedly reduced IgG and IgM, and absent B cells on flow; genetic testing reveals λ5 surrogate light chain gene mutation. λ5 is a component of the surrogate light chain in the pre‑B cell receptor (pre‑BCR). A λ5 defect prevents assembly/signaling of the pre‑BCR, leading to an early block in B‑cell development with profound B‑cell lymphopenia and pan‑hypogammaglobulinemia.\\n\\nOption C (“Absence of the pre-B cell receptor complex signaling”) directly reflects the consequence of a λ5 mutation and best explains the immunologic abnormality. \\n\\nWhy others are worse: A (failure of heavy-chain rearrangement) implicates μ heavy-chain recombination, not λ5; heavy chain must already be successfully rearranged for λ5 to be relevant. B (RAG deficiency) causes SCID with T- and B-cell defects, not an isolated B-cell abnormality due specifically to λ5. D (BLNK mutation) and E (BTK loss) describe other pre‑BCR signaling/maturation defects (e.g., agammaglobulinemia) but are distinct molecular lesions and not caused by a λ5 mutation.\\n\\nMain medical/logical issues: None significant; the mechanistic mapping is accurate. \\n\\nMinimal fix: Explicitly state that T-cell numbers are normal to further distinguish from RAG‑associated SCID, though not strictly necessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 28-year-old woman with recurrent sinopulmonary infections and bronchiectasis; labs show absent IgA, markedly reduced IgG and IgM, and absent B cells on flow; genetic testing reveals λ5 surrogate light chain gene mutation. λ5 is a component of the surrogate light chain in the pre‑B cell receptor (pre‑BCR). A λ5 defect prevents assembly/signaling of the pre‑BCR, leading to an early block in B‑cell development with profound B‑cell lymphopenia and pan‑hypogammaglobulinemia.\n\nOption C (“Absence of the pre-B cell receptor complex signaling”) directly reflects the consequence of a λ5 mutation and best explains the immunologic abnormality. \n\nWhy others are worse: A (failure of heavy-chain rearrangement) implicates μ heavy-chain recombination, not λ5; heavy chain must already be successfully rearranged for λ5 to be relevant. B (RAG deficiency) causes SCID with T- and B-cell defects, not an isolated B-cell abnormality due specifically to λ5. D (BLNK mutation) and E (BTK loss) describe other pre‑BCR signaling/maturation defects (e.g., agammaglobulinemia) but are distinct molecular lesions and not caused by a λ5 mutation.\n\nMain medical/logical issues: None significant; the mechanistic mapping is accurate. \n\nMinimal fix: Explicitly state that T-cell numbers are normal to further distinguish from RAG‑associated SCID, though not strictly necessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-009", "question": "A 42-year-old immigrant from rural Venezuela presents with progressive dyspnea and hemoptysis. Echocardiography shows severe pulmonary hypertension with right ventricular hypertrophy. Serology is positive for Strongyloides stercoralis antibodies. CT chest reveals diffuse ground-glass opacities with bronchial wall thickening. What is the most appropriate initial treatment?", "options": ["Ivermectin alone", "Ivermectin plus prednisone", "Albendazole plus diethylcarbamazine", "Praziquantel followed by ivermectin", "Thiabendazole with gradual pulmonary vasodilator therapy"], "answer": "B", "answer_index": 1, "explanation": "This presentation suggests Strongyloides hyperinfection syndrome with associated pulmonary involvement. Treatment requires both anthelminthic therapy (ivermectin) and corticosteroids to prevent lethal inflammatory response from dying larvae (paradoxical worsening). Using ivermectin alone risks fatal inflammatory reaction. Albendazole is less effective for Strongyloides. Praziquantel treats schistosomiasis, not strongyloidiasis. Vasodilators don't address the underlying parasitic infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Misleading/incorrect; no listed option is an appropriate initial treatment.\\nKey stem clues: Immigrant from endemic area, Strongyloides serology positive, pulmonary involvement (ground-glass opacities, hemoptysis), severe pulmonary hypertension and RVH. This is compatible with chronic strongyloidiasis with possible pulmonary complications; “hyperinfection” is plausible but not clearly proven (no immunosuppression, septic picture, or disseminated disease described). Standard therapy for strongyloidiasis or hyperinfection is ivermectin alone (often repeated dosing); corticosteroids are a known risk factor that can precipitate or worsen hyperinfection, not a protective adjunct. The explanation’s claim that steroids are needed to “prevent lethal inflammatory response” is not supported by mainstream guidance.\\nMain logical issue(s): The keyed answer (B) is contrary to standard of care; none of the other options correctly pair accepted drugs and indications either, leaving no defensible best choice. The stem’s emphasis on pulmonary hypertension is not integrated into answer options.\\nMain medical accuracy issue(s): Reversal of steroid role; incorrect management principle.\\nMinimal fix: Change key to A and revise explanation to standard ivermectin monotherapy for strongyloidiasis/hyperinfection, or adjust stem to justify steroids for another condition entirely.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Misleading/incorrect; no listed option is an appropriate initial treatment.\nKey stem clues: Immigrant from endemic area, Strongyloides serology positive, pulmonary involvement (ground-glass opacities, hemoptysis), severe pulmonary hypertension and RVH. This is compatible with chronic strongyloidiasis with possible pulmonary complications; “hyperinfection” is plausible but not clearly proven (no immunosuppression, septic picture, or disseminated disease described). Standard therapy for strongyloidiasis or hyperinfection is ivermectin alone (often repeated dosing); corticosteroids are a known risk factor that can precipitate or worsen hyperinfection, not a protective adjunct. The explanation’s claim that steroids are needed to “prevent lethal inflammatory response” is not supported by mainstream guidance.\nMain logical issue(s): The keyed answer (B) is contrary to standard of care; none of the other options correctly pair accepted drugs and indications either, leaving no defensible best choice. The stem’s emphasis on pulmonary hypertension is not integrated into answer options.\nMain medical accuracy issue(s): Reversal of steroid role; incorrect management principle.\nMinimal fix: Change key to A and revise explanation to standard ivermectin monotherapy for strongyloidiasis/hyperinfection, or adjust stem to justify steroids for another condition entirely.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-010", "question": "A 65-year-old liver transplant recipient on tacrolimus, mycophenolate, and prednisone presents with altered mental status and focal neurological deficits. MRI shows multiple ring-enhancing lesions with eccentric target sign. CSF PCR is positive for JC virus. What is the most appropriate management?", "options": ["Reduce immunosuppression and initiate intravenous cidofovir", "Immediate exchange transfusion to reduce tacrolimus levels", "Switch from mycophenolate to everolimus and add mirtazapine", "Administer brincidofovir and intravenous immunoglobuli", "Empiric treatment with pyrimethamine/sulfadiazine for toxoplasmosis"], "answer": "C", "answer_index": 2, "explanation": "This is progressive multifocal leukoencephalopathy (PML) in an immunocompromised host. The cornerstone is reducing immunosuppression, specifically switching from mycophenolate (which strongly inhibits T-cell function) to everolimus (which has anti-neoplastic properties and may slow PML progression). Mirtazapine has shown potential benefit by blocking 5-HT2A receptors that JC virus uses for entry. Cidofovir is ineffective against JC virus. Exchange transfusion is not indicated. Antitoxoplasma therapy would be incorrect with positive JC virus PCR.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible) \\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: Liver transplant recipient on tacrolimus/mycophenolate/prednisone; altered mental status with focal deficits; MRI ring-enhancing lesions (though PML classically non–ring-enhancing) with “eccentric target sign”; CSF PCR positive for JC virus. Diagnosis: PML in a solid-organ transplant recipient. Standard management is reduction/modification of immunosuppression; no proven specific antiviral exists.\\n\\nOption C: “Switch from mycophenolate to everolimus and add mirtazapine” is partially speculative. Use of mirtazapine is off-label/low-quality evidence; routine switch specifically to everolimus for PML is not guideline-based. The explanation overstates evidence and mislabels everolimus as having specific benefit for PML. \\nOption A: “Reduce immunosuppression and initiate intravenous cidofovir” includes an incorrect antiviral (cidofovir not effective) but does state the correct cornerstone—reduce immunosuppression—which option C never explicitly states. Thus each has a mix of correct and incorrect elements, and neither cleanly represents standard of care, making best-answer selection ambiguous.\\n\\nMain medical issue: Exaggerated claims for everolimus/mirtazapine; omission of explicit immunosuppression reduction in C. \\nMinimal fix: Modify C to “Reduce overall immunosuppression, including discontinuing mycophenolate, and consider adjunctive mirtazapine;” remove everolimus and cidofovir from choices.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible) \nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: Liver transplant recipient on tacrolimus/mycophenolate/prednisone; altered mental status with focal deficits; MRI ring-enhancing lesions (though PML classically non–ring-enhancing) with “eccentric target sign”; CSF PCR positive for JC virus. Diagnosis: PML in a solid-organ transplant recipient. Standard management is reduction/modification of immunosuppression; no proven specific antiviral exists.\n\nOption C: “Switch from mycophenolate to everolimus and add mirtazapine” is partially speculative. Use of mirtazapine is off-label/low-quality evidence; routine switch specifically to everolimus for PML is not guideline-based. The explanation overstates evidence and mislabels everolimus as having specific benefit for PML. \nOption A: “Reduce immunosuppression and initiate intravenous cidofovir” includes an incorrect antiviral (cidofovir not effective) but does state the correct cornerstone—reduce immunosuppression—which option C never explicitly states. Thus each has a mix of correct and incorrect elements, and neither cleanly represents standard of care, making best-answer selection ambiguous.\n\nMain medical issue: Exaggerated claims for everolimus/mirtazapine; omission of explicit immunosuppression reduction in C. \nMinimal fix: Modify C to “Reduce overall immunosuppression, including discontinuing mycophenolate, and consider adjunctive mirtazapine;” remove everolimus and cidofovir from choices.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-011", "question": "A 34-year-old woman presents with progressive visual field loss. MRI reveals a large suprasellar mass extending into the third ventricle with homogeneous enhancement. Endoscopic biopsy shows a mixed glial and neuronal tumor with neurocytic rosettes and perivascular pseudorosettes. Genetic analysis demonstrates BRAF V600E mutation. What is the most appropriate surgical strategy?", "options": ["Attempt gross total resection via endoscopic endonasal approach", "Subtotal resection followed by targeted BRAF inhibitor therapy", "Open craniotomy with interhemispheric transcallosal approach", "Lateral ventricle endoscopic resection with third ventriculostomy", "Stereotactic biopsy followed by conformal radiotherapy"], "answer": "B", "answer_index": 1, "explanation": "The histology describes a papillary glioneuronal tumor, a low-grade neoplasm with favorable prognosis. When BRAF V600E mutation is present, targeted therapy with BRAF inhibitors can achieve significant tumor reduction with less surgical morbidity compared to aggressive resection for this deeply located tumor. Gross total resection risks hypothalamic injury given the suprasellar location. Radiotherapy is reserved for progressive disease after medical therapy. The transcallosal approach would provide inadequate exposure for this primarily suprasellar lesion.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible, also U/possibly K). Verdict on keyed answer: Not uniquely determinable as best. \\n\\nKey stem clues: 34-year-old woman, progressive visual field loss; MRI: large suprasellar mass extending into third ventricle with homogeneous enhancement; endoscopic biopsy: mixed glial/neuronal tumor with neurocytic and perivascular pseudorosettes; BRAF V600E mutation; question asks for “most appropriate surgical strategy.” Explanation calls it a papillary glioneuronal tumor (PGNT), low-grade, deep, near hypothalamus.\\n\\nLogical issues: The question explicitly asks for the best *surgical* strategy, but choice B is primarily an adjuvant/medical strategy (“Subtotal resection followed by targeted BRAF inhibitor therapy”), blending surgery and systemic therapy and assuming targeted therapy is available/standard first-line for PGNT, which is not firmly established. For a deeply seated low-grade suprasellar mass, a planned subtotal resection to debulk/decompress (often via an open or sometimes endonasal route) is defensible, but no option cleanly states “maximal safe debulking” without binding to BRAF inhibitors. Thus more than one option can be argued against, and none clearly emerges as the uniquely best *surgical* answer. Also, the reliance on BRAF-inhibitor therapy as standard first-line is somewhat ahead of consensus. \\n\\nMinimal fix: Reword the stem to ask for “most appropriate overall management strategy” and/or revise B to “Planned subtotal resection for decompression followed by adjuvant BRAF inhibitor therapy,” clarifying intent and ensuring unique best answer.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible, also U/possibly K). Verdict on keyed answer: Not uniquely determinable as best. \n\nKey stem clues: 34-year-old woman, progressive visual field loss; MRI: large suprasellar mass extending into third ventricle with homogeneous enhancement; endoscopic biopsy: mixed glial/neuronal tumor with neurocytic and perivascular pseudorosettes; BRAF V600E mutation; question asks for “most appropriate surgical strategy.” Explanation calls it a papillary glioneuronal tumor (PGNT), low-grade, deep, near hypothalamus.\n\nLogical issues: The question explicitly asks for the best *surgical* strategy, but choice B is primarily an adjuvant/medical strategy (“Subtotal resection followed by targeted BRAF inhibitor therapy”), blending surgery and systemic therapy and assuming targeted therapy is available/standard first-line for PGNT, which is not firmly established. For a deeply seated low-grade suprasellar mass, a planned subtotal resection to debulk/decompress (often via an open or sometimes endonasal route) is defensible, but no option cleanly states “maximal safe debulking” without binding to BRAF inhibitors. Thus more than one option can be argued against, and none clearly emerges as the uniquely best *surgical* answer. Also, the reliance on BRAF-inhibitor therapy as standard first-line is somewhat ahead of consensus. \n\nMinimal fix: Reword the stem to ask for “most appropriate overall management strategy” and/or revise B to “Planned subtotal resection for decompression followed by adjuvant BRAF inhibitor therapy,” clarifying intent and ensuring unique best answer.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-012", "question": "A 72-year-old man with metastatic castration-resistant prostate cancer to bones undergoes palliative radiotherapy to a symptomatic lumbar spine metastasis (8 Gy × 1). Two weeks later, he develops sudden onset bilateral lower extremity weakness and numbness. MRI shows new T2 hyperintensity in the thoracolumbar cord extending beyond the radiation field. What is the most likely diagnosis?", "options": ["Radiation myelopathy", "Leptomeningeal carcinomatosis", "Paraneoplastic myelitis associated with anti-amphiphysin antibodies", "Spinal cord infarction from tumor embolus", "Subacute combined degeneration from B12 deficiency"], "answer": "C", "answer_index": 2, "explanation": "This presentation describes a paraneometric myelitis triggered by radiation-induced tumor cell death releasing antigens, not direct radiation toxicity (which occurs after longer latency and respects radiation fields). Prostate cancer is associated with anti-amphiphysin antibodies that can cause myelitis. Leptomeningeal disease would show enhancement on MRI. Radiation myelopathy typically presents 6-24 months post-treatment. Cord infarction would have acute dramatic onset rather than subacute progression.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: Elderly man with metastatic castration‑resistant prostate cancer, recent single‑fraction palliative spine RT (8 Gy ×1) to lumbar level; 2 weeks later develops sudden bilateral leg weakness and numbness; MRI shows new T2 hyperintensity in thoracolumbar cord extending beyond radiation field.\\nThe item’s reasoning depends on diagnosing a paraneoplastic/immune-mediated myelitis shortly after RT and excluding radiation myelopathy due to timing and field-respecting pattern. However, nothing in the stem supports specifically “anti‑amphiphysin” antibodies or even clearly distinguishes paraneoplastic myelitis from other inflammatory/ischemic etiologies; MRI description is nonspecific (no mention of enhancement pattern, diffusion restriction, CSF, or systemic autoimmune signs). The claim that prostate cancer is associated with anti-amphiphysin antibodies is not well‑established paraneoplastic dogma, making the keyed option tenuous. Other options are also poorly supported, but the stem does not provide enough specific data to uniquely select C as best; the answer requires accepting the explanation’s speculative mechanism.\\nMedical accuracy: The timing/field argument against radiation myelopathy is correct, but the paraneoplastic association and mechanism are weakly supported.\\nMinimal fix: Explicitly state positive paraneoplastic/autoimmune workup (e.g., “serum anti‑amphiphysin antibodies are detected”) or specify classic longitudinally extensive, enhancing inflammatory myelitis to justify choice C.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: Elderly man with metastatic castration‑resistant prostate cancer, recent single‑fraction palliative spine RT (8 Gy ×1) to lumbar level; 2 weeks later develops sudden bilateral leg weakness and numbness; MRI shows new T2 hyperintensity in thoracolumbar cord extending beyond radiation field.\nThe item’s reasoning depends on diagnosing a paraneoplastic/immune-mediated myelitis shortly after RT and excluding radiation myelopathy due to timing and field-respecting pattern. However, nothing in the stem supports specifically “anti‑amphiphysin” antibodies or even clearly distinguishes paraneoplastic myelitis from other inflammatory/ischemic etiologies; MRI description is nonspecific (no mention of enhancement pattern, diffusion restriction, CSF, or systemic autoimmune signs). The claim that prostate cancer is associated with anti-amphiphysin antibodies is not well‑established paraneoplastic dogma, making the keyed option tenuous. Other options are also poorly supported, but the stem does not provide enough specific data to uniquely select C as best; the answer requires accepting the explanation’s speculative mechanism.\nMedical accuracy: The timing/field argument against radiation myelopathy is correct, but the paraneoplastic association and mechanism are weakly supported.\nMinimal fix: Explicitly state positive paraneoplastic/autoimmune workup (e.g., “serum anti‑amphiphysin antibodies are detected”) or specify classic longitudinally extensive, enhancing inflammatory myelitis to justify choice C.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-013", "question": "A 58-year-old man undergoes left lower lobectomy for stage IIA NSCLC. On postoperative day 2, he develops productive cough and low-grade fever. Chest tube output increases to 450 mL/day of serosanguinous fluid. Fluid analysis shows pH 7.25, glucose 45 mg/dL, LDH 485 U/L. What is the most appropriate management?", "options": ["Insertion of a second chest tube", "Immediate return to operating room for exploration", "Initiation of broad-spectrum antibiotics alone", "Video-assisted thoracoscopic drainage and pleural irrigation", "Observation with repeat chest radiograph in 24 hours"], "answer": "D", "answer_index": 3, "explanation": "The fluid characteristics (low pH, low glucose, elevated LDH) indicate an early empyema or complicated parapneumonic effusion. VATS allows direct visualization, breakdown of loculations, thorough irrigation, and precise tube placement. A second chest tube may not address localized infection. Reoperation is premature without attempted minimally invasive drainage. Antibiotics alone won't drain the infected space. Observation risks progression to fibrinopurulent stage.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: POD2 after lobectomy; new productive cough and low-grade fever; increased serosanguinous chest tube output; pleural fluid with low pH (7.25), low glucose (45 mg/dL), and elevated LDH (485 U/L). These findings characterize a complicated parapneumonic effusion/early empyema rather than a simple postoperative effusion. Management of complicated parapneumonic effusion requires drainage plus antibiotics, and VATS drainage/irrigation is guideline-consistent, particularly in a postoperative thoracic surgery patient where direct visualization and debridement are advantageous.\\nOption appraisal: A (second chest tube) may help drainage but is inferior to VATS in suspected empyema due to loculations and need for debridement. B (immediate open reoperation) is excessive before less invasive VATS. C (antibiotics alone) is inadequate for low pH/low glucose effusions. E (observation) contradicts standard care for complicated effusions. Thus D is the single best answer.\\nMedical accuracy: Fluid criteria and management approach match current standards (e.g., pH <7.2, low glucose). No major inaccuracies.\\nMinimal fix: Explicitly state pleural imaging shows loculated effusion to further justify VATS over an additional tube, though current wording already supports D as best.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: POD2 after lobectomy; new productive cough and low-grade fever; increased serosanguinous chest tube output; pleural fluid with low pH (7.25), low glucose (45 mg/dL), and elevated LDH (485 U/L). These findings characterize a complicated parapneumonic effusion/early empyema rather than a simple postoperative effusion. Management of complicated parapneumonic effusion requires drainage plus antibiotics, and VATS drainage/irrigation is guideline-consistent, particularly in a postoperative thoracic surgery patient where direct visualization and debridement are advantageous.\nOption appraisal: A (second chest tube) may help drainage but is inferior to VATS in suspected empyema due to loculations and need for debridement. B (immediate open reoperation) is excessive before less invasive VATS. C (antibiotics alone) is inadequate for low pH/low glucose effusions. E (observation) contradicts standard care for complicated effusions. Thus D is the single best answer.\nMedical accuracy: Fluid criteria and management approach match current standards (e.g., pH <7.2, low glucose). No major inaccuracies.\nMinimal fix: Explicitly state pleural imaging shows loculated effusion to further justify VATS over an additional tube, though current wording already supports D as best.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-014", "question": "A 68-year-old woman with a history of thoracic endovascular aortic repair (TEVAR) for descending aortic aneurysm presents with hoarseness and dysphagia. Barium swallow shows external compression of the esophagus without mucosal abnormality. Which management strategy addresses the most likely etiology while minimizing procedural risk?", "options": ["Revision TEVAR with proximal extension", "Direct laryngoscopy with vocal cord medialization", "Esophageal stent placement", "CT angiography of the chest with 3D reconstruction", "Open surgical aneurysm repair via left thoracotomy"], "answer": "D", "answer_index": 3, "explanation": "Hoarseness suggests recurrent laryngeal nerve palsy, and dysphagia indicates mechanical compression-findings consistent with a newly enlarging aortic aneurysm at the TEVAR landing zone causing mass effect. CTA provides definitive evaluation of aneurysm size and relationship to adjacent structures. Endoscopy may show compression but cannot characterize the extracesophageal cause. Revision TEVAR or open repair would be premature without demonstrating aneurysm growth. Mere observation misses the opportunity for timely intervention if expansion is confirmed.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Prior TEVAR for descending aortic aneurysm; new hoarseness (recurrent laryngeal nerve involvement) and dysphagia; barium swallow showing external compression without mucosal disease. These suggest mass effect from aneurysm enlargement or endograft-related complication at or near the landing zone. Among options, the safest and most appropriate next step is diagnostic imaging to define the vascular pathology: CT angiography with 3D reconstruction (D).\\nOption appraisal: A (revision TEVAR) and E (open repair) are definitive treatments but premature without updated imaging, and thus higher risk before confirming pathology. B (vocal cord medialization) addresses hoarseness symptomatically but not the underlying cause, and ignores dysphagia/compression. C (esophageal stent) is inappropriate for extrinsic esophageal compression from suspected aneurysmal disease. D accurately targets the most likely etiology (aneurysm growth or endograft complication) while minimizing procedural risk.\\nMedical accuracy: The pathophysiologic reasoning and management sequence align with standard vascular and thoracic practice; no major inaccuracies identified.\\nMinimal fix: Clarify stem’s intent by adding “What is the most appropriate next step in management?” to emphasize diagnostic step before intervention and reduce potential misinterpretation toward immediate repair choices.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Prior TEVAR for descending aortic aneurysm; new hoarseness (recurrent laryngeal nerve involvement) and dysphagia; barium swallow showing external compression without mucosal disease. These suggest mass effect from aneurysm enlargement or endograft-related complication at or near the landing zone. Among options, the safest and most appropriate next step is diagnostic imaging to define the vascular pathology: CT angiography with 3D reconstruction (D).\nOption appraisal: A (revision TEVAR) and E (open repair) are definitive treatments but premature without updated imaging, and thus higher risk before confirming pathology. B (vocal cord medialization) addresses hoarseness symptomatically but not the underlying cause, and ignores dysphagia/compression. C (esophageal stent) is inappropriate for extrinsic esophageal compression from suspected aneurysmal disease. D accurately targets the most likely etiology (aneurysm growth or endograft complication) while minimizing procedural risk.\nMedical accuracy: The pathophysiologic reasoning and management sequence align with standard vascular and thoracic practice; no major inaccuracies identified.\nMinimal fix: Clarify stem’s intent by adding “What is the most appropriate next step in management?” to emphasize diagnostic step before intervention and reduce potential misinterpretation toward immediate repair choices.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-015", "question": "A 47-year-old woman with situs inversus totalis presents with recurrent episodes of acute pancreatitis. MRCP shows pancreas divisum with Santorinicole in the dorsal duct. Previous minor papilla sphincterotomy provided only temporary relief. What is the most appropriate definitive management?", "options": ["Total pancreatectomy with islet autotransplantation", "Long-term pancreatic stent placement across the minor papilla", "Endoscopic ultrasound-guided gastroenterostomy creation", "Surgical dorsal duct jejunostomy (Puestow procedure)", "Repeat ERCP with extended sphincterotomy and stricture dilation"], "answer": "A", "answer_index": 0, "explanation": "In the setting of situs inversus with complex pancreatic duct anatomy (Santorinicole) and failed sphincterotomy, TP-IAT offers the only definitive solution for recurrent pancreatitis while preserving endocrine function. The anomalous anatomy makes standard drainage procedures (Puestow) technically challenging and less effective. Long-term stenting leads to ductal changes and strictures. EUS-guided drainage would not address the underlying drainage impairment from the Santorinicole.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer\\nKey stem clues: 47-year-old woman; situs inversus totalis; pancreas divisum with Santorinicole in the dorsal duct; recurrent acute pancreatitis; prior minor papilla sphincterotomy with only temporary relief; question asks for “most appropriate definitive management.”\\nMain logical issues: Total pancreatectomy with islet autotransplantation (TP-IAT) is an extreme, last-resort option for intractable painful chronic pancreatitis, not standard “most appropriate definitive management” for recurrent acute pancreatitis due to pancreas divisum after a single endoscopic attempt. No option reflects accepted next steps such as repeat/minor papilla therapy, advanced endoscopic drainage, or a tailored surgical drainage/resection procedure; thus none is clearly defensible as best. Dorsal duct jejunostomy (Puestow-type) is not a standard operation for divisum, and the stem’s invocation of “Santorinicole” and situs inversus is vague and not tied to clear guideline-based management. The rationale exaggerates TP-IAT as “only definitive solution,” which is not aligned with consensus.\\nMain medical accuracy issues: Overstatement of TP-IAT indication; mischaracterization of alternatives; nonstandard terminology. \\nMinimal fix: Replace options so that one reflects guideline-consistent escalation (e.g., surgical minor papilla/dorsal duct drainage) and key that option; or revise stem to end-stage chronic pancreatitis clearly refractory to all drainage, then key TP-IAT.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer\nKey stem clues: 47-year-old woman; situs inversus totalis; pancreas divisum with Santorinicole in the dorsal duct; recurrent acute pancreatitis; prior minor papilla sphincterotomy with only temporary relief; question asks for “most appropriate definitive management.”\nMain logical issues: Total pancreatectomy with islet autotransplantation (TP-IAT) is an extreme, last-resort option for intractable painful chronic pancreatitis, not standard “most appropriate definitive management” for recurrent acute pancreatitis due to pancreas divisum after a single endoscopic attempt. No option reflects accepted next steps such as repeat/minor papilla therapy, advanced endoscopic drainage, or a tailored surgical drainage/resection procedure; thus none is clearly defensible as best. Dorsal duct jejunostomy (Puestow-type) is not a standard operation for divisum, and the stem’s invocation of “Santorinicole” and situs inversus is vague and not tied to clear guideline-based management. The rationale exaggerates TP-IAT as “only definitive solution,” which is not aligned with consensus.\nMain medical accuracy issues: Overstatement of TP-IAT indication; mischaracterization of alternatives; nonstandard terminology. \nMinimal fix: Replace options so that one reflects guideline-consistent escalation (e.g., surgical minor papilla/dorsal duct drainage) and key that option; or revise stem to end-stage chronic pancreatitis clearly refractory to all drainage, then key TP-IAT.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-016", "question": "A 52-year-old man with alcohol-related cirrhosis presents with acute upper GI bleeding. During emergent endoscopy, active spurting is seen from a large duodenal ulcer in the posterior bulb. After epinephrine injection and placement of two through-the-scope clips, bleeding continues. The following day, he develops fever and severe abdominal pain. CT shows retroperitoneal air and fluid tracking along the right psoas muscle. What is the most appropriate management?", "options": ["Angiographic embolization of the gastroduodenal artery", "Emergency laparotomy with duodenal diversion", "Percutaneous drainage of the retroperitoneal collection", "Repeat endoscopy with over-the-scope clip placement", "IV antibiotics and serial abdominal exams"], "answer": "B", "answer_index": 1, "explanation": "This scenario describes a posterior duodenal ulcer perforation into the retroperitoneum following endoscopic intervention. Given the ongoing bleeding and established contamination, definitive surgical management with duodenal diversion (e.g., Graham patch closure with gastrodujunostomy) is required. Angioembolization would address bleeding but not the perforation. Percutaneous drainage cannot control the duodenal leak. Repeat endoscopy is contraindicated with known perforation. Antibiotics alone would lead to uncontrolled sepsis.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: alcoholic cirrhotic with acute upper GI bleed from a large posterior duodenal bulb ulcer; hemostatic endoscopic therapy fails (continued spurting after injection and clips). Next day: fever, severe abdominal pain, CT with retroperitoneal air and fluid along right psoas → clear posterior duodenal perforation into the retroperitoneum with established contamination and likely ongoing leak, in the setting of recent uncontrolled bleeding.\\n\\nMost likely diagnosis/mechanism: perforated posterior duodenal ulcer with retroperitoneal abscess/contamination plus prior uncontrolled hemorrhage. Standard management is operative: control leak and bleeding ± diversion/definitive ulcer procedure. Thus emergency laparotomy with duodenal diversion (B) is the most appropriate.\\n\\nWhy alternatives are worse: (A) angioembolization treats bleeding but leaves an uncontrolled perforation and contamination. (C) Percutaneous drainage alone does not control the source (ongoing duodenal leak). (D) Repeat endoscopy is contraindicated in suspected perforation. (E) IV antibiotics and observation are inadequate for established perforation with sepsis.\\n\\nMain medical accuracy issue(s): Minor—terminology of “duodenal diversion” could be more specific, but concept is standard. \\n\\nMinimal fix: Clarify in the stem that free contrast or obvious leak from the duodenum is seen on CT to make perforation explicit and remove any residual ambiguity.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: alcoholic cirrhotic with acute upper GI bleed from a large posterior duodenal bulb ulcer; hemostatic endoscopic therapy fails (continued spurting after injection and clips). Next day: fever, severe abdominal pain, CT with retroperitoneal air and fluid along right psoas → clear posterior duodenal perforation into the retroperitoneum with established contamination and likely ongoing leak, in the setting of recent uncontrolled bleeding.\n\nMost likely diagnosis/mechanism: perforated posterior duodenal ulcer with retroperitoneal abscess/contamination plus prior uncontrolled hemorrhage. Standard management is operative: control leak and bleeding ± diversion/definitive ulcer procedure. Thus emergency laparotomy with duodenal diversion (B) is the most appropriate.\n\nWhy alternatives are worse: (A) angioembolization treats bleeding but leaves an uncontrolled perforation and contamination. (C) Percutaneous drainage alone does not control the source (ongoing duodenal leak). (D) Repeat endoscopy is contraindicated in suspected perforation. (E) IV antibiotics and observation are inadequate for established perforation with sepsis.\n\nMain medical accuracy issue(s): Minor—terminology of “duodenal diversion” could be more specific, but concept is standard. \n\nMinimal fix: Clarify in the stem that free contrast or obvious leak from the duodenum is seen on CT to make perforation explicit and remove any residual ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-017", "question": "A 35-year-old woman with tuberous sclerosis complex develops rapidly progressive renal insufficiency. Imaging shows massively enlarged kidneys with innumerable angiomyolipomas, the largest measuring 8 cm. What is the most appropriate intervention to preserve renal function?", "options": ["Selective arterial embolization of the dominant tumors", "Initiation of everolimus therapy", "Bilateral nephrectomy with dialysis initiation", "Cryoablation of the largest angiomyolipomas", "Radical nephrectomy of the more affected kidney"], "answer": "B", "answer_index": 1, "explanation": "In TSC with diffuse angiomyolipomatosis causing renal failure, everolimus (an mTOR inhibitor) is first-line therapy as it targets the underlying pathophysiology, can reduce tumor size by over 50%, and preserves renal function better than procedural interventions. Embolization or ablation would be impractical for innumerable tumors and could accelerate renal decline. Nephrectomy should be avoided unless absolutely necessary for hemorrhage control. Everolimus addresses the systemic nature of TSC renal involvement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with tuberous sclerosis complex, massively enlarged kidneys with innumerable angiomyolipomas, rapidly progressive renal insufficiency, largest lesion 8 cm. The clinical issue is preservation of renal function in diffuse TSC-associated angiomyolipomatosis, not control of a single bleeding lesion.\\nEverolimus (mTOR inhibitor) is guideline-supported first-line systemic therapy for TSC-related renal angiomyolipomas, especially when multiple/bilateral and threatening renal function, due to its ability to shrink tumors and stabilize/improve renal function. Thus choice B is appropriate.\\nOption A (selective arterial embolization) is used mainly for acute/impending hemorrhage or a few large lesions; here innumerable tumors make it less practical and potentially more nephron-destructive. Options C and E (bilateral or unilateral radical nephrectomy) are inappropriate if the goal is to preserve renal function and there is no mention of uncontrollable bleeding or malignancy. D (cryoablation) is similarly local and not well suited for innumerable lesions.\\nNo major medical inaccuracies are evident; the rationale aligns with current TSC management standards.\\nMinimal fix: Explicitly state absence of acute hemorrhage and that the goal is chronic preservation of renal function to further clarify everolimus as best choice.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with tuberous sclerosis complex, massively enlarged kidneys with innumerable angiomyolipomas, rapidly progressive renal insufficiency, largest lesion 8 cm. The clinical issue is preservation of renal function in diffuse TSC-associated angiomyolipomatosis, not control of a single bleeding lesion.\nEverolimus (mTOR inhibitor) is guideline-supported first-line systemic therapy for TSC-related renal angiomyolipomas, especially when multiple/bilateral and threatening renal function, due to its ability to shrink tumors and stabilize/improve renal function. Thus choice B is appropriate.\nOption A (selective arterial embolization) is used mainly for acute/impending hemorrhage or a few large lesions; here innumerable tumors make it less practical and potentially more nephron-destructive. Options C and E (bilateral or unilateral radical nephrectomy) are inappropriate if the goal is to preserve renal function and there is no mention of uncontrollable bleeding or malignancy. D (cryoablation) is similarly local and not well suited for innumerable lesions.\nNo major medical inaccuracies are evident; the rationale aligns with current TSC management standards.\nMinimal fix: Explicitly state absence of acute hemorrhage and that the goal is chronic preservation of renal function to further clarify everolimus as best choice.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-018", "question": "A 6-month-old boy presents with recurrent sinopulmonary infections, failure to thrive, and absent lymph nodes on examination. Flow cytometry shows profoundly decreased T cells with normal B cell numbers. Mitogen proliferation assays show no response. Genetic testing reveals a missense mutation in the ORAI1 gene. What specific immunologic defect is present?", "options": ["Defective thymic epithelial development", "Impaired VDJ recombination in T cell receptors", "Absence of stores operated calcium entry", "Mutation in the ζ-chain-associated protein kinase", "Adenosine deaminase deficiency with metabolic toxicity"], "answer": "C", "answer_index": 2, "explanation": "ORAI1 encodes a calcium release-activated calcium channel essential for store-operated calcium entry (SOCE), which is critical for T cell activation, cytokine production, and immune function. Without SOCE, T cells cannot properly activate despite normal development, explaining the severe combined immunodeficiency presentation with normal lymphocyte numbers but functional impairment. This is distinct from recombination defects (RAG, Artemis) or metabolic deficiencies (ADA). The ORAI1 mutation specifically disrupts calcium signaling after T cell receptor engagement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6‑month-old boy; recurrent sinopulmonary infections and failure to thrive (SCID phenotype); absent lymph nodes; flow cytometry with profoundly decreased *functional* T cells but normal B-cell numbers; mitogen proliferation shows no response (global T-cell activation defect); genetic testing shows missense mutation in ORAI1. ORAI1 is the pore-forming subunit of the CRAC channel mediating store-operated calcium entry (SOCE) after ER Ca²⁺ depletion via STIM1, critical for T-cell activation but not early development. Thus the specific immunologic defect is absence of store-operated calcium entry (choice C).\\nOther options: A (thymic epithelial defect, e.g., DiGeorge) would cause impaired T-cell development, not an ORAI1 calcium-channel defect. B (impaired VDJ recombination) refers to RAG/Artemis defects, not ORAI1. D (ζ-chain-associated protein kinase = ZAP-70 mutation) is a distinct proximal TCR signaling defect. E (ADA deficiency) is a metabolic purine-catabolism defect with lymphotoxicity, unrelated to ORAI1.\\nMain medical/logical issues: Minor inconsistency in stating “profoundly decreased T cells” vs “normal lymphocyte numbers” in rationale, but teaching point (functional defect in SOCE) is correct.\\nMinimal fix: Clarify that T-cell numbers are normal but functionally impaired to align stem and explanation precisely.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6‑month-old boy; recurrent sinopulmonary infections and failure to thrive (SCID phenotype); absent lymph nodes; flow cytometry with profoundly decreased *functional* T cells but normal B-cell numbers; mitogen proliferation shows no response (global T-cell activation defect); genetic testing shows missense mutation in ORAI1. ORAI1 is the pore-forming subunit of the CRAC channel mediating store-operated calcium entry (SOCE) after ER Ca²⁺ depletion via STIM1, critical for T-cell activation but not early development. Thus the specific immunologic defect is absence of store-operated calcium entry (choice C).\nOther options: A (thymic epithelial defect, e.g., DiGeorge) would cause impaired T-cell development, not an ORAI1 calcium-channel defect. B (impaired VDJ recombination) refers to RAG/Artemis defects, not ORAI1. D (ζ-chain-associated protein kinase = ZAP-70 mutation) is a distinct proximal TCR signaling defect. E (ADA deficiency) is a metabolic purine-catabolism defect with lymphotoxicity, unrelated to ORAI1.\nMain medical/logical issues: Minor inconsistency in stating “profoundly decreased T cells” vs “normal lymphocyte numbers” in rationale, but teaching point (functional defect in SOCE) is correct.\nMinimal fix: Clarify that T-cell numbers are normal but functionally impaired to align stem and explanation precisely.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-019", "question": "A 30-year-old missionary presents with a slowly enlarging scalp lesion after returning from Bolivia. biopsy demonstrates lobulated granulomatous inflammation with rare 5-7 μm budding yeast. Culture on brain-heart infusion agar at 25°C shows cream-colored colonies that convert to yeast form at 37°C. What is the most appropriate antifungal therapy?", "options": ["Itraconazole for 6-12 months", "Amphotericin B lipid complex followed by itraconazole", "Voriconazole indefinitely", "Posaconazole with therapeutic drug monitoring", "Fluconazole for 3-6 months"], "answer": "A", "answer_index": 0, "explanation": "The presentation describes cutaneous granulomas caused by Paracoccidioides brasiliensis, endemic to Latin America. Itraconazole is first-line for non-severe disease, with 6-12 months treatment typically achieving cure. Amphotericin B is reserved for severe disseminated disease. Voriconazole has variable activity against Paracoccidioides. Fluconazole is less effective due to higher relapse rates. The dimorphic growth pattern and geographic history are classic for this infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Missionary returning from Bolivia (Latin America); slowly enlarging scalp lesion; biopsy with lobulated granulomatous inflammation and 5–7 μm budding yeast; dimorphic fungus growing as cream colonies on brain–heart infusion agar at 25°C converting to yeast at 37°C. These support diagnosis of paracoccidioidomycosis with cutaneous involvement and non-severe disease.\\n\\nThe keyed answer, itraconazole for 6–12 months, matches standard first-line therapy for mild to moderate paracoccidioidomycosis, including cutaneous disease, with that usual duration. Amphotericin B induction followed by itraconazole (choice B) is indicated for severe or disseminated disease, which is not described here. Voriconazole (C) and posaconazole (D) are not standard first-line agents and have limited or less well-established roles. Fluconazole (E) is less effective with higher relapse rates.\\n\\nThere is no internal contradiction, and one option is clearly best given the non-severe localized lesion. Medical content aligns with accepted management.\\n\\nMinimal fix: Explicitly state that the patient has no systemic symptoms or organ involvement (e.g., “He is otherwise well with no pulmonary or mucosal symptoms”) to further emphasize this is non-severe disease appropriate for itraconazole monotherapy.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Missionary returning from Bolivia (Latin America); slowly enlarging scalp lesion; biopsy with lobulated granulomatous inflammation and 5–7 μm budding yeast; dimorphic fungus growing as cream colonies on brain–heart infusion agar at 25°C converting to yeast at 37°C. These support diagnosis of paracoccidioidomycosis with cutaneous involvement and non-severe disease.\n\nThe keyed answer, itraconazole for 6–12 months, matches standard first-line therapy for mild to moderate paracoccidioidomycosis, including cutaneous disease, with that usual duration. Amphotericin B induction followed by itraconazole (choice B) is indicated for severe or disseminated disease, which is not described here. Voriconazole (C) and posaconazole (D) are not standard first-line agents and have limited or less well-established roles. Fluconazole (E) is less effective with higher relapse rates.\n\nThere is no internal contradiction, and one option is clearly best given the non-severe localized lesion. Medical content aligns with accepted management.\n\nMinimal fix: Explicitly state that the patient has no systemic symptoms or organ involvement (e.g., “He is otherwise well with no pulmonary or mucosal symptoms”) to further emphasize this is non-severe disease appropriate for itraconazole monotherapy.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-020", "question": "A 42-year-old woman with HIV (CD4 180 cells/μL, viral load undetectable on ART) presents with 2 weeks of progressive neurological decline. MRI shows multiple ring-enhancing lesions with minimal edema. CSF PCR is negative for JC virus, toxoplasma, and CMV. Brain biopsy reveals necrotizing encephalitis with bizarre astrocytes and intranuclear viral inclusions. What is the most appropriate treatment?", "options": ["High-dose ganciclovir", "Intravenous foscarnet", "Artemisinin combination therapy", "Pyrimethamine plus sulfadiazine", "Cidofovir with probenecid"], "answer": "B", "answer_index": 1, "explanation": "The histopathological findings are characteristic of cytomegalovirus encephalitis, which can present with atypical MRI findings in immunocompromised hosts. Foscarnet is preferred over ganciclovir in this scenario because CMV encephalitis in HIV patients often occurs despite undetectable plasma viral loads, suggesting possible ganciclovir resistance or poor CNS penetration. Foscarnet has different mechanisms of action and better CNS penetration. The negative CSF PCR does not rule out CMV encephalitis due to low viral loads. Arteminsinin and anti-toxoplasma therapies would not address CMV.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible)\\nVerdict on keyed answer: Misleading; no option clearly fits the described pathology.\\nKey stem clues: HIV patient, CD4 180; MRI with multiple ring-enhancing lesions; CSF PCR negative for JC, toxoplasma, CMV; brain biopsy shows necrotizing encephalitis with bizarre astrocytes and intranuclear viral inclusions. The explanation asserts these are characteristic of CMV encephalitis. In reality, bizarre astrocytes with intranuclear inclusions and necrotizing encephalitis are more typical of HSV or PML-related changes; CMV classically shows cytomegalic cells with intranuclear and intracytoplasmic inclusions in ependymal/subependymal regions. Also, if CMV were correct, ganciclovir (A) is standard first-line; foscarnet (B) is reserved for ganciclovir-resistant disease. No evidence of resistance or ganciclovir failure is provided. Thus the pathologic diagnosis and the treatment choice are both poorly supported. Other options (C, D) target malaria or toxoplasma and are inconsistent with negative tests/biopsy, but among antivirals, standard of care would favor ganciclovir over foscarnet.\\nMain medical accuracy issues: Mischaracterization of CMV histology; incorrect rationale for foscarnet as first-line.\\nMinimal fix: Revise pathology to classic ganciclovir-resistant CMV and explicitly state prior ganciclovir failure, or change key to ganciclovir with corrected explanation.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible)\nVerdict on keyed answer: Misleading; no option clearly fits the described pathology.\nKey stem clues: HIV patient, CD4 180; MRI with multiple ring-enhancing lesions; CSF PCR negative for JC, toxoplasma, CMV; brain biopsy shows necrotizing encephalitis with bizarre astrocytes and intranuclear viral inclusions. The explanation asserts these are characteristic of CMV encephalitis. In reality, bizarre astrocytes with intranuclear inclusions and necrotizing encephalitis are more typical of HSV or PML-related changes; CMV classically shows cytomegalic cells with intranuclear and intracytoplasmic inclusions in ependymal/subependymal regions. Also, if CMV were correct, ganciclovir (A) is standard first-line; foscarnet (B) is reserved for ganciclovir-resistant disease. No evidence of resistance or ganciclovir failure is provided. Thus the pathologic diagnosis and the treatment choice are both poorly supported. Other options (C, D) target malaria or toxoplasma and are inconsistent with negative tests/biopsy, but among antivirals, standard of care would favor ganciclovir over foscarnet.\nMain medical accuracy issues: Mischaracterization of CMV histology; incorrect rationale for foscarnet as first-line.\nMinimal fix: Revise pathology to classic ganciclovir-resistant CMV and explicitly state prior ganciclovir failure, or change key to ganciclovir with corrected explanation.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}]